Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV-1 subtypes A–D
✍ Scribed by Ann Atlas; Tran Thi Thanh Ha; Anna Lindström; Anna Nilsson; Annette Alaeus; Francesca Chiodi; Angelo De Milito
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 155 KB
- Volume
- 72
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
HIV‐1 genetic subtypes might have a different impact on disease progression and response to antiretroviral therapy (ART). Few data are available on the immune activation profile in patients with different HIV‐1 subtypes. We have tested by ELISA the plasma levels of an immune activation marker, soluble CD27 (sCD27), in a cohort of 64 patients infected with HIV‐1 subtypes A–D, at baseline and after 1 year of virologically successful ART. Plasma sCD27 was significantly higher in the whole HIV‐1‐infected population as compared to healthy subjects [522 U/ml (188–1,307) vs. 285 U/ml (174–397), P < 0.001]. Among the four different HIV‐1 subtypes, patients with subtype C virus had significantly higher plasma sCD27 [684 U/ml, (188–1228)] as compared to patients with subtype A [428 U/ml (247–1307), P < 0.05] and B [454 (211–925), P < 0.05]. After 1 year of ART, plasma sCD27 significantly decreased in all groups but patients with subtype C viruses had the largest reduction of sCD27 from baseline. The data indicate that a similar immune activation profile is present in patients infected with HIV‐1 subtypes A, B, and D and that in presence of successful ART these subtypes respond similarly in terms of immune activation. Intriguingly, subtype C infection seems to be associated with higher levels of plasma sCD27, suggesting that HIV‐1 genetic subtype C may have a different impact on disease outcome and response to therapy. J. Med. Virol. 72:345–351, 2004. © 2004 Wiley‐Liss, Inc.